Clinical trial • Phase III • Haematology

IADADEMSTAT for Sickle cell disease

Phase III trial of IADADEMSTAT for Sickle cell disease. 30 participants.

Overview

Trial Therapeutic Area
Haematology
Trial Disease
Sickle cell disease
Trial Stage
Phase III

Key dates

Initial CTIS Submission Date
15-05-2025
First CTIS Authorization Date
20-08-2025

Trial design

Phase III trial across 7 sites in Spain.

Target Sample Size
30

Recruitment

Planned Sample Size
30
Recruitment Window Months
891

Geography

Total Number Of Sites
7
Total Number Of Participants
30

Spain

Earliest CTIS Part Ii Submission Date
16-07-2025
Latest Decision Or Authorization Date
09-12-2025
Processing Time Days
146
Number Of Sites
7
Number Of Participants
30

Sites

Site Name
Institut Catala D'oncologia
Department Name
Hematology
Contact Person Name
Ines Hernández
Contact Person Email
ihernandez@iconcologia.net
Site Name
Hospital Universitario La Paz
Department Name
Hematology
Contact Person Name
Ana Mendoza
Contact Person Email
anamendoz94@gmail.com
Site Name
Hospital De La Santa Creu I Sant Pau
Department Name
Hematology
Contact Person Name
Nuria González
Contact Person Email
NGonzalezAl@santpau.cat
Site Name
Hospital Clínic Barcelona
Department Name
Hematology
Contact Person Name
Meritxell Nomdedeu
Contact Person Email
MNOMDEDEU@clinic.cat
Site Name
Hospital General Universitario Gregorio Maranon
Department Name
Hematology
Contact Person Name
Cristina Pascual
Contact Person Email
cpascuali@salud.madrid.org
Site Name
Hospital Universitari Vall D Hebron
Department Name
Hematology
Contact Person Name
David Beneitez
Contact Person Email
david.beneitez@vallhebron.cat
Site Name
University Hospital Virgen Del Rocio S.L.
Department Name
Hematology
Contact Person Name
Salvador Payán

Sponsor

Primary sponsor

Full Name
Oryzon Genomics S.A.
Organisation Type
Pharmaceutical company
Country Of Registered Address
Spain

Investigational products

Investigational Product Name
IADADEMSTAT

Related trials

Other published trials that may interest you.